Which has stronger earnings & valuation, GMAB or ARGX?

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.72B 4.20 $963M $1.32 19.00 argenex $4.25B 13.08 $1.29B $22.46 39.78

Is GMAB or ARGX more profitable?

argenex has a net margin of 31.31% compared to Genmab A/S's net margin of 21.05%. argenex's return on equity of 44.37% beat Genmab A/S's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% argenex 31.31% 44.37% 37.55%

Does the media refer more to GMAB or ARGX?

In the previous week, argenex had 3 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for argenex and 4 mentions for Genmab A/S. argenex's average media sentiment score of 0.77 beat Genmab A/S's score of 0.47 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GMAB or TAK?

Genmab A/S currently has a consensus target price of $37.93, suggesting a potential upside of 51.23%. Given Genmab A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to GMAB or TAK?

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 4 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.47 beat Takeda Pharmaceutical's score of 0.38 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GMAB or TEVA?

In the previous week, Teva Pharmaceutical Industries had 22 more articles in the media than Genmab A/S. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 4 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat Genmab A/S's score of 0.47 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 21 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GMAB or RVMD?

In the previous week, Revolution Medicines had 3 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Revolution Medicines and 4 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 1.47 beat Genmab A/S's score of 0.47 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GMAB or ONC more profitable?

Genmab A/S has a net margin of 21.05% compared to BeOne Medicines' net margin of 8.94%. Genmab A/S's return on equity of 15.34% beat BeOne Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% BeOne Medicines 8.94% 12.06% 6.69%

Does the media refer more to GMAB or ONC?

In the previous week, BeOne Medicines had 8 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for BeOne Medicines and 4 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.47 beat BeOne Medicines' score of -0.08 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Genmab A/S (GMAB) Competitors

$25.08 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$25.08 +0.01 (+0.02%)

As of 06/12/2026 04:10 PM Eastern

Compare

GMAB vs. ARGX, TAK, TEVA, RVMD, and ONC

Should you buy Genmab A/S stock or one of its competitors? MarketBeat compares Genmab A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genmab A/S include argenex (ARGX), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Genmab A/S compare to argenex?

Genmab A/S (NASDAQ:GMAB) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, argenex had 3 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for argenex and 4 mentions for Genmab A/S. argenex's average media sentiment score of 0.77 beat Genmab A/S's score of 0.47 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.20	$963M	$1.32	19.00
argenex	$4.25B	13.08	$1.29B	$22.46	39.78

Genmab A/S presently has a consensus target price of $37.93, indicating a potential upside of 51.23%. argenex has a consensus target price of $1,019.50, indicating a potential upside of 14.10%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Genmab A/S has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

argenex has a net margin of 31.31% compared to Genmab A/S's net margin of 21.05%. argenex's return on equity of 44.37% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
argenex	31.31%	44.37%	37.55%

Summary

argenex beats Genmab A/S on 15 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Takeda Pharmaceutical?

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Genmab A/S has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.20	$963M	$1.32	19.00
Takeda Pharmaceutical	$28.32B	1.79	$1.27B	$0.39	40.81

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 21.05% compared to Takeda Pharmaceutical's net margin of 4.31%. Genmab A/S's return on equity of 15.34% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 4 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.47 beat Takeda Pharmaceutical's score of 0.38 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S currently has a consensus target price of $37.93, suggesting a potential upside of 51.23%. Given Genmab A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Genmab A/S (NASDAQ:GMAB) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Genmab A/S has a net margin of 21.05% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

In the previous week, Teva Pharmaceutical Industries had 22 more articles in the media than Genmab A/S. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 4 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 1.38 beat Genmab A/S's score of 0.47 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	21 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.20	$963M	$1.32	19.00
Teva Pharmaceutical Industries	$17.26B	2.30	$1.41B	$1.33	26.00

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Genmab A/S has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Genmab A/S currently has a consensus target price of $37.93, indicating a potential upside of 51.23%. Teva Pharmaceutical Industries has a consensus target price of $41.78, indicating a potential upside of 20.83%. Given Genmab A/S's higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Teva Pharmaceutical Industries beats Genmab A/S on 10 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Revolution Medicines?

Genmab A/S (NASDAQ:GMAB) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Revolution Medicines had 3 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for Revolution Medicines and 4 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 1.47 beat Genmab A/S's score of 0.47 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.20	$963M	$1.32	19.00
Revolution Medicines	$11.58M	2,824.94	-$1.13B	-$7.07	N/A

Genmab A/S has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Genmab A/S currently has a consensus target price of $37.93, suggesting a potential upside of 51.23%. Revolution Medicines has a consensus target price of $123.72, suggesting a potential downside of 19.59%. Given Genmab A/S's higher possible upside, equities research analysts clearly believe Genmab A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

Genmab A/S has a net margin of 21.05% compared to Revolution Medicines' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

Revolution Medicines beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to BeOne Medicines?

Genmab A/S (NASDAQ:GMAB) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Genmab A/S currently has a consensus price target of $37.93, suggesting a potential upside of 51.23%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 47.46%. Given Genmab A/S's higher probable upside, equities analysts plainly believe Genmab A/S is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Genmab A/S has a net margin of 21.05% compared to BeOne Medicines' net margin of 8.94%. Genmab A/S's return on equity of 15.34% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, BeOne Medicines had 8 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for BeOne Medicines and 4 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.47 beat BeOne Medicines' score of -0.08 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has higher earnings, but lower revenue than BeOne Medicines. Genmab A/S is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.20	$963M	$1.32	19.00
BeOne Medicines	$5.34B	5.43	$286.93M	$4.47	59.17

Genmab A/S has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats Genmab A/S on 10 of the 17 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMAB vs. The Competition

Export

Metric	Genmab A/S	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.64B	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	19.00	19.82	24.21	24.42
Price / Sales	4.20	305.69	512.04	109.94
Price / Cash	15.58	53.61	27.48	37.92
Price / Book	2.76	8.32	10.66	6.83
Net Income	$963M	$23.94M	$3.57B	$337.67M
7 Day Performance	1.13%	1.84%	0.58%	1.17%
1 Month Performance	-5.50%	-0.04%	1.54%	3.16%
1 Year Performance	9.90%	44.82%	25.40%	30.58%

Genmab A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMAB Genmab A/S	4.424 of 5 stars	$25.08 flat	$37.93 +51.2%	+9.9%	$15.64B	$3.72B	19.00	3,029
ARGX argenex	4.0745 of 5 stars	$882.41 -1.0%	$1,019.50 +15.5%	+54.6%	$55.43B	$4.25B	39.29	1,863	News Coverage Analyst Forecast
TAK Takeda Pharmaceutical	3.1561 of 5 stars	$15.78 +1.1%	N/A	+4.7%	$49.65B	$28.32B	40.45	47,455	News Coverage
TEVA Teva Pharmaceutical Industries	4.5477 of 5 stars	$33.24 -2.8%	$41.78 +25.7%	+103.4%	$39.31B	$17.26B	24.99	33,950	Positive News
RVMD Revolution Medicines	1.7875 of 5 stars	$148.49 -0.5%	$123.72 -16.7%	+279.1%	$31.73B	$11.58M	N/A	250	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMAB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Competitors

GMAB vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Genmab A/S compare to argenex?

Summary

How does Genmab A/S compare to Takeda Pharmaceutical?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Summary

How does Genmab A/S compare to Revolution Medicines?

Summary

How does Genmab A/S compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genmab A/S (GMAB) Competitors

GMAB vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Genmab A/S compare to argenex?

Do insiders & institutionals believe in GMAB or ARGX?

Does the media refer more to GMAB or ARGX?

Which has stronger earnings & valuation, GMAB or ARGX?

Do analysts rate GMAB or ARGX?

Which has more volatility and risk, GMAB or ARGX?

Is GMAB or ARGX more profitable?

Summary

How does Genmab A/S compare to Takeda Pharmaceutical?

Which has more risk and volatility, GMAB or TAK?

Which has preferable earnings & valuation, GMAB or TAK?

Do institutionals and insiders hold more shares of GMAB or TAK?

Is GMAB or TAK more profitable?

Does the media refer more to GMAB or TAK?

Do analysts prefer GMAB or TAK?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Is GMAB or TEVA more profitable?

Does the media prefer GMAB or TEVA?

Which has better valuation & earnings, GMAB or TEVA?

Do insiders and institutionals have more ownership in GMAB or TEVA?

Which has more risk & volatility, GMAB or TEVA?

Do analysts recommend GMAB or TEVA?

Summary

How does Genmab A/S compare to Revolution Medicines?

Does the media prefer GMAB or RVMD?

Do insiders & institutionals hold more shares of GMAB or RVMD?

Which has higher earnings & valuation, GMAB or RVMD?

Which has more risk and volatility, GMAB or RVMD?

Do analysts recommend GMAB or RVMD?

Is GMAB or RVMD more profitable?

Summary

How does Genmab A/S compare to BeOne Medicines?

Do insiders and institutionals have more ownership in GMAB or ONC?

Do analysts recommend GMAB or ONC?

Is GMAB or ONC more profitable?

Does the media refer more to GMAB or ONC?

Which has higher valuation & earnings, GMAB or ONC?

Which has more risk & volatility, GMAB or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools